Meeting
2014 ASCO Annual Meeting
Effect of clinical NGS-based cancer genomic profiling on physician treatment decisions in advanced solid tumors.
Authors
Fadi S. Braiteh
Comprehensive Cancer Centers of Nevada, Las Vegas, NV, and US Oncology Research, Houston, TX
Fadi S. Braiteh , Jeff Porter Sharman , Donald A. Richards , Matthew Rama Skelton , Linda Cheryl DeMarco , Sasha Vukelja , Ian Schnadig , Sharon Wilks , Christopher A. Yasenchak , Jerome H. Goldschmidt , Regina Resta , Stephen Lane Richey , John W. Smith II, Lina Asmar , Yunfei Wang , Ann Morcos , Tracy Locke , Yali Li , Gary A. Palmer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11109)
DOI
10.1200/jco.2014.32.15_suppl.11109
Abstract #
11109
Poster Bd #
391
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Clinical utility of tumor next-generational sequencing (NGS) panel testing to inform treatment decisions for patients with advanced solid tumors.
First Author: Lucia Bogdan
Poster
2018 ASCO Annual Meeting
Use of next-generation sequencing tests to guide cancer treatment: Results from a survey of U.S. oncologists.
First Author: Andrew N. Freedman
Poster
2024 ASCO Annual Meeting
Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).
First Author: Heejung Chae
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The genomic landscape of patients with advanced colorectal adenocarcinoma with PIK3CA mutations using comprehensive cell free tumor DNA next generation sequencing.
First Author: Nilesh Verma